Avita Medical to Hold ReCell(R) Symposium at Leading European Burns Association Course
NORTHRIDGE, CA and PERTH, AUSTRALIA and LONDON, UNITED KINGDOM--(Marketwired - Sep 22, 2016) - Avita Medical Ltd (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, said today it will host a ReCell® Symposium at the EBA Educational Course, taking place in Birmingham, UK, 26-27 September.
The Symposium 'Experiences of ReCell® in burns treatment and scar revision' will support the education and adoption of new technologies and share the experiences of lead clinicians who have used ReCell® for burns. The Symposium is taking place at 9.10 a.m. during Session 4: Post burn reconstruction C. Speakers taking part in the Symposium are:
Ms Isabel Jones - Plastic Surgeon, Chelsea and Westminster Hospital London
Professor Matthias Aust - Plastic and Aesthetic Surgeon, Malteser Hospital, Bonn
Dr Shehzadi Kohli - Plastic, Reconstructive, Hand, Aesthetic and Burn Surgeon - Klinikum Bogenhausen, Munich
Dr Simon Kuepper - Plastic and Aesthetic Surgeon, Unfallkrankenhaus, Berlin
Dr Christopher Dunnill - University of Huddersfield
The EBA Educational Course is a bi-annual event which sees 300 delegates, including plastic surgeons, anesthesiologists, nurse specialists and burn team members from Europe and beyond. This year's theme is Burns at the Extremes of Age, incorporating acute care and resuscitation, infection and sepsis, skin substitutes; present and future and psychological aspects of burns.
To meet the Avita team, visit Stand 8 in the exhibition hall.
ABOUT AVITA MEDICAL LIMITED
Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. approval trial is underway. To learn more, visit www.avitamedical.com.
ReCell® is a medical device which enables clinicians to safely and rapidly create a treatment solution for burns and acute injuries from a patient's own skin.
Using a small sample of skin, the device enables the production of a Regenerative Epithelial Suspension (RES™). The autologous suspension contains the multi-phenotype cells and wound-healing factors essential for natural healthy skin regeneration and healing. The procedure performed at the patient's bedside takes about 30 minutes from collecting the biopsy to spraying of the suspension onto the affected area.
ReCell® can be used in conjunction with conventional treatments for burns and reconstructive procedures, and has been used safely in thousands of treatments worldwide. Recent data showed that treatment of ReCell® decreased length of hospital stay in patients with large burns by 47%.
For more information, visit: http://avitamedical.com/clinicians/burns-clinician/how-it-works
FOR FURTHER INFORMATION
Avita Medical Ltd
Chief Executive Officer
Phone: +44 (0) 1763 269 772
Avita Medical Ltd
Chief Financial Officer
Phone: + 1 (818) 356-9400
Avita Medical Ltd
Phone +61(0) 8 9474 7738
Gemma Howe/Sue Charles
Phone +44 (0)20 7866 7860
Phone: +61 3 9620 3333
Mobile: +61 (0) 411 698 499
This information is provided by RNS